LXRX

Lexicon Pharmaceuticals Inc

• Benzinga·03/30 12:04

  Avis Budget Group, Toyota Motor And Other Big Stocks Moving Lower In Monday's Pre-Market Session

• Reuters·03/24 12:05

  Lexicon to present Phase 3 SCORED and SOTA-P-CARDIA sotagliflozin data at ACC 2026

• Dow Jones·03/23 15:30

  Lexicon Pharma Price Target Maintained With a $6.00/Share by HC Wainwright & Co.

• Benzinga·03/23 15:20

  HC Wainwright & Co. Reiterates Buy on Lexicon Pharmaceuticals, Maintains $6 Price Target

• TipRanks·03/23 14:30

  Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Lexicon Pharmaceuticals (LXRX)

• Dow Jones·03/23 12:05

  Novo Nordisk Begins Study of Lexicon Oral Obesity Drug

• TipRanks·03/23 11:46

  Lexicon, Novo Nordisk announce initiation of LX9851 study

• Benzinga·03/23 11:38

  Lexicon Pharmaceuticals And Novo Nordisk Initiate Phase 1 Study With LX9851, An Oral Non-incretin Development Candidate, For Obesity And Associated Metabolic Disorders

• Reuters·03/23 11:31

  Novo Nordisk initiates Phase 1 trial of Lexicon-licensed obesity candidate LX9851

• Reuters·03/23 11:30

  LEXICON PHARMACEUTICALS INC - EARNS SECOND $10 MLN MILESTONE; ELIGIBLE FOR UP TO $1 BLN IN PAYMENTS

• Reuters·03/23 11:30

  LEXICON PHARMACEUTICALS INC - PHASE 1 STUDY OF LX9851 EXPECTED TO COMPLETE IN Q1 2027

• TipRanks·03/12 16:40

  Analysts’ Opinions Are Mixed on These Healthcare Stocks: Rapid Micro Biosystems (RPID), Lexicon Pharmaceuticals (LXRX) and Whitehawk Therapeutics (WHWK)

• TipRanks·03/11 12:17

  Lexicon announces results from post hoc analysis on data of sotagliflozin

• Benzinga·03/11 12:12

  Lexicon Pharmaceuticals Says sotagliflozin Improves Cardiometabolic Outcomes In Type 1 Diabetes Regardless Of Kidney Function; New Analysis To Be Presented At ATTD 2026